{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:14:40Z","timestamp":1793042080425,"version":"4.5.0"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T00:00:00Z","timestamp":1762560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002336","name":"Daiichi Sankyo Co., Ltd.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"<jats:title>AbstractAbstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Gliomas are primary brain tumors arising from glial cells. WHO grade 2 gliomas are initially managed with surgery for diagnosis and tumor reduction. However, complete resection is difficult due to their infiltrative growth into the normal brain and the need to preserve brain function. Current treatment options for WHO grade 2 gliomas are limited. Isocitrate dehydrogenase 1 (IDH1) mutations are frequently observed in WHO grade 2 gliomas. Safusidenib erbumine is a selective inhibitor of mutant IDH1 with substantial blood-brain barrier penetration. This study aimed to investigate the efficacy and safety of safusidenib erbumine in patients with chemotherapy- and radiotherapy-na\u00efve IDH1-mutated WHO grade 2 gliomas.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This phase II study implemented a multicenter, open-label, single-arm design and evaluated the efficacy and safety of safusidenib erbumine in 27 patients with chemotherapy- and radiotherapy-na\u00efve IDH1-mutated WHO grade 2 gliomas (NCT04458272).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The confirmed objective response rate according to the Response Assessment in Neuro-Oncology criteria for WHO grade 2 gliomas was 44.4%. Median progression-free survival was not reached, with an event-free probability of 87.9% at 24 months. The frequently reported treatment-emergent adverse events (TEAEs) by Medical Dictionary for Regulatory Activities Preferred Terms (reported in \u226540%) were alopecia (59.3%), arthralgia (55.6%), skin hyperpigmentation (48.1%), and alanine aminotransferase increased (40.7%). Treatment-emergent adverse events were characterized as mostly grade 1 or 2. The incidence of treatment-related grade \u22653 TEAEs was 18.5%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Safusidenib erbumine is a potential treatment option for patients with chemotherapy- and radiotherapy-na\u00efve IDH1-mutated WHO grade 2 gliomas.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/neuonc\/noaf258","type":"journal-article","created":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T11:24:05Z","timestamp":1762687445000},"page":"717-727","source":"Crossref","is-referenced-by-count":4,"title":["Phase II study of safusidenib erbumine in patients with chemotherapy- and radiotherapy-na\u00efve isocitrate dehydrogenase 1-mutated WHO grade 2 gliomas"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4626-4645","authenticated-orcid":false,"given":"Yoshiki","family":"Arakawa","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Graduate School of Medicine, Kyoto University , Kyoto (Y.A.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2484-1360","authenticated-orcid":false,"given":"Ryuta","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Graduate School of Medicine, Nagoya University , Nagoya (R.S., K.Mo.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonehiro","family":"Kanemura","sequence":"additional","affiliation":[{"name":"Department of Biomedical Research and Innovation, Institute for Clinical Research, Osaka (Y.Kan.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Mishima","sequence":"additional","affiliation":[{"name":"Department of Neuro-Oncology\/Neurosurgery, Saitama Medical University International Medical Center, Hidaka (K.Mi.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunichi","family":"Koriyama","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Tokyo Women\u2019s Medical University, Tokyo (S.K.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4303-6006","authenticated-orcid":false,"given":"Yoshitaka","family":"Narita","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, Tokyo (Y.N.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Kumabe","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Kitasato University School of Medicine, Sagamihara (T.K)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Motomura","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Graduate School of Medicine, Nagoya University , Nagoya (R.S., K.Mo.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Sugiyama","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology & Neuro-Oncology Program, Hiroshima University Hospital, Hiroshima (K.S)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0164-6295","authenticated-orcid":false,"given":"Fumiyuki","family":"Yamasaki","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Hiroshima University Hospital, Hiroshima (F.Y.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akitake","family":"Mukasa","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto (A.M.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3380-1192","authenticated-orcid":false,"given":"Masayuki","family":"Kanamori","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Tohoku University Graduate School of Medicine, Sendai (M.K.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Kuga","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka (D.K.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0018-1652","authenticated-orcid":false,"given":"Motoo","family":"Nagane","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Kyorin University Faculty of Medicine, Tokyo (M.N.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Kakurai","sequence":"additional","affiliation":[{"name":"Data Intelligence Department, Daiichi Sankyo Co., Ltd , Tokyo (Y.Kak.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Isobe","sequence":"additional","affiliation":[{"name":"Clinical Science Department, Daiichi Sankyo Co., Ltd , Tokyo (K.I.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Kurume University School of Medicine , Kurume (H.N.)"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,8]]},"reference":[{"key":"2026041216245188300_noaf258-B1","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"key":"2026041216245188300_noaf258-B2","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","article-title":"EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood","volume":"18","author":"Weller","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"2026041216245188300_noaf258-B3","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJMoa2304194","article-title":"Vorasidenib in IDH1- or IDH2-mutant low-grade glioma","volume":"389","author":"Mellinghoff","year":"2023","journal-title":"N Engl J Med"},{"key":"2026041216245188300_noaf258-B4","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1158\/1535-7163.MCT-18-1349","article-title":"A potent blood-brain barrier-permeable mutant IDH1 inhibitor suppresses the growth of glioblastoma with IDH1 mutation in a patient-derived orthotopic xenograft model","volume":"19","author":"Machida","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"2026041216245188300_noaf258-B5","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/neuonc\/noac155","article-title":"The first-in-human phase I study of a brain-penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas","volume":"25","author":"Natsume","year":"2023","journal-title":"Neuro Oncol"},{"key":"2026041216245188300_noaf258-B6","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/ng.3273","article-title":"Mutational landscape and clonal architecture in grade II and III gliomas","volume":"47","author":"Suzuki","year":"2015","journal-title":"Nat Genet"},{"key":"2026041216245188300_noaf258-B7","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00401-013-1141-6","article-title":"Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total lp19q loss","volume":"126","author":"Arita","year":"2013","journal-title":"Acta Neuropathol"},{"key":"2026041216245188300_noaf258-B8","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1158\/1078-0432.CCR-13-3052","article-title":"Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas","volume":"20","author":"Wakimoto","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2026041216245188300_noaf258-B9","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/ng.3457","article-title":"Integrated genomic characterization of IDH1- mutant glioma malignant progression","volume":"48","author":"Bai","year":"2016","journal-title":"Nat Genet"},{"key":"2026041216245188300_noaf258-B10","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S1470-2045(11)70057-2","article-title":"Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas","volume":"12","author":"van den Bent","year":"2011","journal-title":"Lancet Oncol"},{"key":"2026041216245188300_noaf258-B11","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00401-010-0725-7","article-title":"Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician\u2019s perspective","volume":"120","author":"van den Bent","year":"2010","journal-title":"Acta Neuropathol"},{"key":"2026041216245188300_noaf258-B12","doi-asserted-by":"crossref","first-page":"61","DOI":"10.4103\/0028-3886.93594","article-title":"Concordance between local, institutional, and central pathology review in glioblastoma: implications for research and practice: a pilot study","volume":"60","author":"Gupta","year":"2012","journal-title":"Neurol India"},{"key":"2026041216245188300_noaf258-B13","author":"US Food and Drug Administration","year":"2025"},{"key":"2026041216245188300_noaf258-B14","author":"US Food and Drug Administration","year":"2022"},{"key":"2026041216245188300_noaf258-B15","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.str.2016.12.017","article-title":"Allosteric mutant IDH1 inhibitors reveal mechanisms for IDH1 mutant and isoform selectivity","volume":"25","author":"Xie","year":"2017","journal-title":"Structure"},{"key":"2026041216245188300_noaf258-B16","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1093\/neuonc\/noac139","article-title":"Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: a multicenter, open-label, phase Ib\/II trial","volume":"25","author":"de la Fuente","year":"2023","journal-title":"Neuro Oncol"},{"key":"2026041216245188300_noaf258-B17","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1158\/1078-0432.CCR-20-0834","article-title":"Differentiation syndrome with ivosidenib and enasidenib treatment in patients with relapsed or refractory IDH-Mutated AML: a U.S. Food and Drug Administration systematic analysis","volume":"26","author":"Norsworthy","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026041216245188300_noaf258-B18","doi-asserted-by":"crossref","first-page":"1305714","DOI":"10.3389\/fmed.2024.1305714","article-title":"Frequency of IDH1 mutation in adult-type diffuse astrocytic gliomas in a tertiary hospital in Kenya","volume":"11","author":"Gakinya","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"2026041216245188300_noaf258-B19","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2176\/jns-nmc.2021-0313","article-title":"Malignant progression of diffuse low-grade gliomas: a systematic review and meta-analysis on incidence and related factors","volume":"62","author":"Nakasu","year":"2022","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"2026041216245188300_noaf258-B20","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/neuonc\/nox195","article-title":"Radiation-induced cognitive toxicity: pathophysiology and interventions to reduce toxicity in adults","volume":"20","author":"Wilke","year":"2018","journal-title":"Neuro Oncol"},{"key":"2026041216245188300_noaf258-B21","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1007\/s11764-015-0439-x","article-title":"Hormonal dysfunction is frequent in cancer survivors treated with radiotherapy to the head and neck region","volume":"9","author":"Seland","year":"2015","journal-title":"J Cancer Surviv"},{"key":"2026041216245188300_noaf258-B22","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1093\/neuonc\/not036","article-title":"Secondary hematological malignancies associated with temozolomide in patients with glioma","volume":"15","author":"Momota","year":"2013","journal-title":"Neuro Oncol"}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noaf258\/65247025\/noaf258.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/28\/3\/717\/65247025\/noaf258.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/28\/3\/717\/65247025\/noaf258.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T20:25:03Z","timestamp":1776025503000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/28\/3\/717\/8317259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,8]]},"references-count":22,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,11,8]]},"published-print":{"date-parts":[[2026,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noaf258","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2025,11,8]]}}}